Skip to main content
GutCited

N-Acetyl Cysteine (NAC) pour Inflammatory Bowel Disease (IBD) — General

D

Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dinflammatory\u002Dbowel\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

En conclusion

Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.

Key Study Findings

Review
Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases.
Dose: None vs: None Outcome: None Effet: None None

Population: Review of nanocatalytic antioxidation in diseases

Randomized Controlled Trial 16 weeks Open-label
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury …
Dose: N-acetylcysteine with thiopurine vs: Thiopurine alone (crossover) Outcome: Liver injury markers and oxidative stress Effet: None None

Population: IBD patients with thiopurine-induced liver injury

Review
The emerging role of oxidative stress in inflammatory bowel disease.
Dose: None vs: None Outcome: Oxidative stress role in IBD pathophysiology Effet: None None

Population: IBD patients (Crohn's and UC)

In Vitro 4.3 weeks
Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney.
Dose: 150 mg/kg vs: None Outcome: inflammation markers Effet: None None

Population: Mice

Systematic Review 52 weeks
Vitamin D for the treatment of inflammatory bowel disease.
Dose: 400 IU/day vs: placebo Outcome: IBD disease activity Effet: None None

Population: Patients with IBD

Review
Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease …
Dose: None vs: None Outcome: Ferroptosis role in IBD pathogenesis Effet: None None

Population: IBD patients (mechanistic review)

Key Statistics

1

Études

30

Participants

Positive

D

Note

Referenced Papers

Frontiers in endocrinology 2024 165 citations
Pharmaceuticals (Basel, Switzerland) 2023 18 citations
The Cochrane database … 2023 1 citations
European journal of … 2021 40 citations
The British journal … 2012 145 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
600-1,200 mg/day in divided doses
hpyloriadjunct:
600 mg twice daily alongside standard triple therapy
antioxidantsupport:
600-900 mg/day

Limite supérieure : Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Mixed --
N-acetylcysteine with thiopurine 16 weeks Positive --
None -- Positive --
150 mg/kg 4.3 weeks Positive --
400 IU/day 52 weeks Mixed --
None -- Neutral --
Various antioxidant compounds -- Positive --
None -- Mixed --

Moment optimal de prise : With or without food; divide doses throughout the day

Safety & Side Effects

Effets indésirables signalés

  • Nausea and vomiting (most common, especially at higher doses)
  • Diarrhea
  • Unpleasant sulfur taste/odor
  • Headache

Interactions connues

  • Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
  • Activated charcoal (may reduce NAC absorption)
  • Anticoagulants (NAC may have mild antiplatelet effects)
  • ACE inhibitors (additive hypotensive effect with nitroglycerin combination)

Apport maximal tolérable : Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does N-Acetyl Cysteine (NAC) help with Inflammatory Bowel Disease (IBD) — General?
Based on 1 studies with 30 participants, there is preliminary evidence that needs more research that N-Acetyl Cysteine (NAC) may support Inflammatory Bowel Disease (IBD) — General management. Our evidence grade is D (Very Early Research).
How much N-Acetyl Cysteine (NAC) should I take for Inflammatory Bowel Disease (IBD) — General?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Inflammatory Bowel Disease (IBD) — General?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 30 total participants. The overall direction of effect is positive.

Related Evidence

Autres ingrédients pour Inflammatory Bowel Disease (IBD) — General

N-Acetyl Cysteine (NAC) pour d'autres pathologies

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.